Target intelligence / Profile preview

FK506-binding protein 12 F36V mutant fusion protein (FKBP12(F36V) fusion protein)

Target
FKBP12(F36V) fusion protein
Molecular classification
Engineered protein tag, Immunophilin-derived construct, Peptidyl-prolyl isomerase domain fusion
01

Overview

FKBP12(F36V) fusion protein is an engineered construct used extensively in chemical biology and synthetic biology research. It is based on the human FK506-binding protein 12 (FKBP12), a member of the immunophilin family, with a specific F36V point mutation that creates a binding cavity of approximately 90 cubic angstroms[1]. This single amino acid substitution (phenylalanine to valine at position 36) generates a complementary pocket that allows selective binding to synthetic ligands containing a structural "bump," such as Shield-1 and SLF' derivatives[7]. The F36V mutation provides remarkable selectivity, with engineered ligands binding approximately 1,000 to 1,600-fold more tightly to FKBP12(F36V) compared to wild-type FKBP12[5][7]. This high affinity (subnanomolar Kd) and specificity make FKBP12(F36V) an exceptionally useful tag for diverse applications in living cells and animal models. The fusion protein serves multiple research purposes. It can be genetically fused to proteins of interest for fluorescent labeling using dye-conjugated ligands like FL-SLF', enabling visualization at low expression levels with minimal background staining[2][5]. Modified versions incorporating the L106P mutation create destabilizing domains (DDs) that render fusion proteins unstable and subject to degradation unless stabilized by small molecules like Shield-1, allowing reversible control of protein levels[3][7]. More recently, heterobifunctional molecules called dTAGs have been developed that recruit E3 ubiquitin ligases (CRBN or VHL) to induce rapid, targeted degradation of FKBP12(F36V)-tagged proteins[9]. The system has been optimized through various modifications, including neutralization of charged surface residues to prevent electrostatic interference with fusion partner function, and removal of cryptic Cre-LoxP sites for compatibility with conditional gene expression systems[3]. FKBP12(F36V) fusions have been successfully applied to membrane proteins, cytoplasmic proteins, nuclear proteins, and enzymes across multiple cell types and even in zebrafish and mouse models, demonstrating broad versatility for manipulating protein function in a specific, rapid, reversible, and tunable manner[2][3][5].

Other names
FKBP12(F36V) fusionFKBP(F36V) fusion proteinF36V-FKBP fusionFKBP12 F36V-tagged proteinFKBPF36V-fusion protein
02

Mechanism of action

Ligand-dependent protein stabilization (with Shield-1); Targeted protein degradation via PROTAC mechanism (with dTAG molecules recruiting E3 ubiquitin ligases like VHL or CRBN); High-affinity binding-mediated fluorescent labeling; Chemical-induced dimerization for signaling activation

03

Biological functions

Protein labeling and visualizationChemical-induced protein degradationConditional protein stability regulationFluorescent tagging for live cell imagingTargeted protein inactivation via FALI (fluorophore-assisted laser inactivation)
04

Disease associations

This is a research tool rather than a disease-associated target, so disease roles are not directly applicable. However, it has been used to study proteins involved in cancer, developmental disorders, and various signaling pathways.
05

Safety considerations

Potential electrostatic interference with fusion protein function (addressed in modified versions with neutralized surface charges)Possible interference with endogenous FKBP12 functionBackground signal in some labeling applicationsNeed for careful optimization of expression levels to avoid biological artifacts from overexpression
06

Interacting drugs

Shield-1

5 more in the full profile.

07

Biomarkers

Not applicable as this is a research tool rather than a clinical target

Beyond the preview

Go deeper on FK506-binding protein 12 F36V mutant fusion protein (FKBP12(F36V) fusion protein).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on FK506-binding protein 12 F36V mutant fusion protein (FKBP12(F36V) fusion protein).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call